Q2 FY2026 EarningsQ2 FY26 results slightly exceeded consensus on the bottom line, with a GAAP net loss of -$11.5M vs. -$12.0M expected, and GAAP EPS of -$0.48 vs. the -$0.48 mean estimate. While revenue remains at zero as expected for this clinical-stage biotech, R&D expenses rose to $9.0M due to Phase 1b/2 enrollment for TH103. The cash runway was extended into Q4 2027, providing sufficient liquidity through key Phase 1b/2 preliminary data expected in 1H 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Kalaris Therapeutics(KLRS) the EBIT is -12.39 M (-1.06%), Beat estimate;the EPS is -0.48 (+21.31%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.01B1.06%
-0.01B1.39%
+0.00B0.33%
EPSExceed expectations
-0.4821.31%
-0.483320.77%
+0.00330.54%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf